Cargando…
Comparison of lung microbiota between antineutrophil cytoplasmic antibody-associated vasculitis and sarcoidosis
Microbial involvement in the pathogenesis have been suggested in both antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and sarcoidosis, both of which have lung involvement. However, exhaustive research to assess the bacteria in the lung in AAV and in sarcoidosis have not been performe...
Autores principales: | Fukui, Shoichi, Morimoto, Shimpei, Ichinose, Kunihiro, Nakashima, Shota, Ishimoto, Hiroshi, Hara, Atsuko, Kakugawa, Tomoyuki, Sakamoto, Noriho, Tsuji, Yoshika, Aramaki, Toshiyuki, Koga, Tomohiro, Kawashiri, Shin-ya, Iwamoto, Naoki, Tamai, Mami, Nakamura, Hideki, Origuchi, Tomoki, Ueki, Yukitaka, Suzuki, Shino, Mukae, Hiroshi, Kawakami, Atsushi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7289840/ https://www.ncbi.nlm.nih.gov/pubmed/32528054 http://dx.doi.org/10.1038/s41598-020-66178-4 |
Ejemplares similares
-
Antineutrophilic cytoplasmic antibody-associated vasculitis with hypocomplementemia has a higher incidence of serious organ damage and a poor prognosis
por: Fukui, Shoichi, et al.
Publicado: (2016) -
Fewer subsequent relapses and lower levels of IL-17 in Takayasu arteritis developed after the age of 40 years
por: Fukui, Shoichi, et al.
Publicado: (2016) -
Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2017) -
Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled
por: Kawashiri, Shin-ya, et al.
Publicado: (2017) -
Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010
por: Ichinose, Kunihiro, et al.
Publicado: (2018)